Data / Drug companies / Chiesi USA, Inc.
Chiesi USA, Inc.: 21 products in the FDA NDC directory, labeler code 10122
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Chiesi USA, Inc. (labeler code 10122) lists 21 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 21 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on February 25, 2026.
The request: Watch Chiesi USA, Inc. (FDA labeler code 10122): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 10122
- Products in commercial distribution
- 21
- Packages
- 29
- Finished drugs by generic name
- 13
- Prescription products
- 21
- Over the counter products
- 0
- Flagged as original packager
- 21 of 21 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- December 6, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 15 | 71.4% |
| Biologics (BLA) | 6 | 28.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 21 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lomitapide mesylate | 5 | 2 |
| Deferiprone | 3 | 5 |
| Pegunigalsidase alfa | 2 | 1 |
| Clevipidine | 2 | 1 |
| Elapegademase-lvlr | 1 | 1 |
| Velmanase alfa-tycv | 1 | 1 |
| Octreotide | 1 | 2 |
| Tobramycin | 1 | 41 |
| Zileuton | 1 | 6 |
| Cangrelor | 1 | 2 |
| Poractant alfa | 1 | 1 |
| Metreleptin | 1 | 1 |
| Birch triterpenes | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 5 | 23.8% |
| Injection, powder, lyophilized, for solution | 3 | 14.3% |
| Solution | 2 | 9.5% |
| Tablet | 2 | 9.5% |
| Injection, solution, concentrate | 2 | 9.5% |
| Emulsion | 2 | 9.5% |
| Injection | 1 | 4.8% |
| Capsule, delayed release | 1 | 4.8% |
| Suspension | 1 | 4.8% |
| Tablet, film coated | 1 | 4.8% |
| Gel | 1 | 4.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Microsomal Triglyceride Transfer Protein Inhibitor | 5 |
| Iron Chelator | 3 |
| Dihydropyridine Calcium Channel Blocker | 2 |
| Somatostatin Analog | 1 |
| Aminoglycoside Antibacterial | 1 |
| 5-Lipoxygenase Inhibitor | 1 |
| P2Y12 Platelet Inhibitor | 1 |
| Surfactant | 1 |
| Leptin Analog | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Juxtapid | 10122-402 | Capsule | New drug applications (NDA) | February 25, 2026 |
| Filsuvez | 10122-310 | Gel | New drug applications (NDA) | February 22, 2024 |
| Elfabrio | 10122-165 | Injection, solution, concentrate | Biologics (BLA) | May 23, 2023 |
| Elfabrio | 10122-160 | Injection, solution, concentrate | Biologics (BLA) | May 23, 2023 |
| Lamzede | 10122-180 | Injection, powder, lyophilized, for solution | Biologics (BLA) | March 1, 2023 |
| Mycapssa | 10122-550 | Capsule, delayed release | New drug applications (NDA) | July 6, 2020 |
| Ferriprox | 10122-104 | Tablet | New drug applications (NDA) | May 19, 2020 |
| Ferriprox | 10122-103 | Tablet, film coated | New drug applications (NDA) | August 1, 2019 |
| Revcovi | 10122-502 | Injection | Biologics (BLA) | October 5, 2018 |
| Ferriprox | 10122-101 | Solution | New drug applications (NDA) | September 9, 2015 |
| Kengreal | 10122-620 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | July 8, 2015 |
| Myalept | 10122-210 | Injection, powder, lyophilized, for solution | Biologics (BLA) | March 5, 2015 |
| Bethkis | 10122-820 | Solution | New drug applications (NDA) | April 15, 2013 |
| Juxtapid | 10122-430 | Capsule | New drug applications (NDA) | January 3, 2013 |
| Juxtapid | 10122-420 | Capsule | New drug applications (NDA) | January 3, 2013 |
| Juxtapid | 10122-410 | Capsule | New drug applications (NDA) | January 3, 2013 |
| Juxtapid | 10122-405 | Capsule | New drug applications (NDA) | January 3, 2013 |
| Cleviprex | 10122-611 | Emulsion | New drug applications (NDA) | September 15, 2008 |
| Cleviprex | 10122-610 | Emulsion | New drug applications (NDA) | September 15, 2008 |
| Curosurf | 10122-510 | Suspension | Biologics (BLA) | November 18, 1999 |
| Zyflo | 10122-901 | Tablet | New drug applications (NDA) | December 6, 1996 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.